Galmed Pharmaceuticals Ltd.
Business
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company developing Aramchol, a first-in-class oral SCD1 modulator candidate for liver diseases and gastrointestinal malignancies, supported by a Phase 3 open-label study and preclinical research. The company is also developing Amilo-5MER, an immunomodulator for chronic inflammatory diseases, currently seeking partners for out-licensing. Galmed operates through research collaborations and licensing agreements, including a Korean commercialization license with Samil and oncology research partnerships with Virginia Commonwealth University. The company has no manufacturing operations and relies on contract manufacturers and CROs for development and clinical trial execution.
Summary from 20-F filed 2026-03-31
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-10.31M |
| Total assets | $18.63M |
| Total liabilities | — |
| Stockholders' equity | $15.78M |
| Operating cash flow | $-6.32M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Galmed Pharmaceuticals Ltd.'s CIK number?
Galmed Pharmaceuticals Ltd.'s SEC CIK number is 0001595353 (1595353). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Galmed Pharmaceuticals Ltd.'s SEC filings?
All of Galmed Pharmaceuticals Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.